Compare two antibiotics for hard-to-treat E. coli and Klebsiella bloodstream infections
Treatments studied
Part of Infections clinical trials.
This trial tests whether piperacillin-tazobactam works as well as meropenem to treat bloodstream infections caused by certain E. coli or Klebsiella germs that resist common cephalosporin antibiotics. It may help you avoid a “bigger” antibiotic if the study drug is equally effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult (18 years or older).
- Your bloodstream infection started recently, and blood cultures show E. coli or Klebsiella (in one or more blood culture bottles).
- The germ is not susceptible to common 3rd-generation cephalosporin antibiotics (like ceftriaxone or ceftazidime) but is susceptible to both study antibiotics (piperacillin-tazobactam and meropenem).
- The first positive blood culture was taken within the last 72 hours (not later).
- This infection is not a mixed infection with multiple different germ species in the same episode.
- You’re not in severe shock at enrollment, and you don’t have certain specific infections (heart valve infection, bone infection that isn’t removed, or brain/spinal cord infection).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two common antibiotics, meropenem and piperacillin/tazobactam, to see which works better for adults with sepsis who are critically ill. It aims to help doctors choose the best treatment for serious infections.
This study watches how safely two common antibiotics (vancomycin and a combination called piperacillin/tazobactam) work together in hospitalized patients with serious infections. Researchers want to make sure the combination doesn't harm kidney function.
This trial studies whether cefiderocol plus ampicillin-sulbactam works better than colistin (sometimes with meropenem) for serious infections caused by carbapenem-resistant Acinetobacter baumannii (a hard-to-treat germ). It may help by finding a more effective antibiotic plan for people with these severe hospital-acquired infections.
This trial tests whether a newer antibiotic (ceftolozane/tazobactam) works as well as the standard drug (meropenem) for treating fever and low white blood cell counts in people who carry or are at risk for a certain type of resistant bacteria (ESBL). If you are colonized with ESBL or have recently used certain antibiotics, you may be eligible.
This trial tests whether the antibiotic cefotetan works as well as current standard treatments for E. coli bloodstream infections that start in the urinary tract. If you qualify, you may receive either cefotetan or the usual antibiotic therapy.
This trial tests a combination of two antibiotics (cefepime and enmetazobactam) to treat complicated urinary tract infections that have spread to the blood. It aims to see if this new combination works better than other antibiotics and is safe for patients.
Hear when a new Enterobacteriaceae Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.